about
The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironmentIn vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesChemokine nitration prevents intratumoral infiltration of antigen-specific T cells.Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.Role of arginine metabolism in immunity and immunopathology.Therapeutic targeting of myeloid-derived suppressor cells.Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.MDSCs in cancer: Conceiving new prognostic and therapeutic targets.Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer modelsPreventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
P50
Q28396481-2D5ECCAD-852F-435A-A7B8-9EFF3A31CD50Q33671654-2454ECFA-5D29-4812-A4A4-29579AB62C5AQ34044797-922024B7-DE0A-45EC-98E9-E14E1575F666Q35237477-055F3A61-6612-4B2D-9EE7-0636F3162A7CQ36004284-72FB01DB-35AC-4276-B41A-943D80C11923Q36568998-F54F7FDB-3FEC-48FC-8B65-1D05FFCC6E6CQ37034571-AC99638D-59F7-4A3E-AFB8-3E313362928DQ37555487-B665E2B3-6676-4C80-A63B-CCCED0E8D3FCQ37679962-1A030F11-3695-4F5B-B635-4B0A9E2FDABDQ38563094-919DC494-C7A9-4E6D-83D3-3312D97096C9Q38565385-DDBEE292-8EEE-483A-98EA-B9E3B911004CQ38769825-914E3C04-DA02-4CA8-B016-6BBD0964246CQ39283369-557948D9-80A3-48FF-89D8-3CA6C87CDACAQ39725373-A4EE2042-9F76-48B3-B434-AE8D3E45C784Q39770285-241C2B1F-A86F-48C0-AA33-B5FC54DB8238Q39776441-680B88AF-D968-45C3-B65B-E40B5121E70DQ41990676-B54E92FF-3FAF-49F6-A9A5-F0694CE5B543Q47204382-38D71206-517B-4207-9C11-458901965C62Q54421148-C5D916F2-9538-4A66-AAEF-65419C626A0EQ91972406-3D844F02-0538-444B-88F0-1324ABAAD864
P50
description
researcher ORCID ID = 0000-0002-6639-7608
@en
name
Stefano Ugel
@ast
Stefano Ugel
@en
Stefano Ugel
@es
Stefano Ugel
@nl
type
label
Stefano Ugel
@ast
Stefano Ugel
@en
Stefano Ugel
@es
Stefano Ugel
@nl
prefLabel
Stefano Ugel
@ast
Stefano Ugel
@en
Stefano Ugel
@es
Stefano Ugel
@nl
P1153
14120516300
P21
P31
P496
0000-0002-6639-7608